COPENHAGEN (Reuters) -The Danish medicines agency on Monday warned of a supply shortage for two separate doses of Novo Nordisk’s hugely popular weight loss drug Wegovy due to increasing demand.
Wegovy is given by weekly injection and belong to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes.
There will be a shortage of Novo Nordisk’s Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
There will also be a shortage of Novo’s 0.5 milligram Wegovy Flextouch pen between mid-June and mid-July, it added.
Novo Nordisk did not immediately respond to a request for comment.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
Comments